NCT01299558 - Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate and GW642444 Are Processed by the Body in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 17, 2010

Primary Completion Date

July 15, 2010

Study Completion Date

July 15, 2010

Conditions

Asthma

Interventions

DRUG

fluticasone furoate//GW642444

Single inhaled dose of FF (800mcg)/GW642444M (100mcg) Inhalation Powder administered in the morning

DRUG

fluticasone furoate

Single IV dose of FF (250mcg)

DRUG

GW642444

Single IV dose of GW642444 (55mcg)

Trial Locations (1)

GSK Investigational Site, Randwick